Cephalexin

Generic Name: Cephalexin

Brand Names: Keflex

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₇N_₃O_₄S

CAS Number: 15686-71-2

Unique Ingredient Identifier: 5SFF1W6677

Background: Cephalexin is the first of the first generation cephalosporins. This antibiotic contains a beta lactam and a dihydrothiazide. Cephalexin is used to treat a number of susceptible bacterial infections through inhibition of cell wall synthesis. Cephalexin was approved by the FDA on 4 January 1971.

Indication: Cephalexin is indicated for the treatment of certain infections caused by susceptible bacteria. These infections include respiratory tract infections, otitis media, skin and skin structure infections, bone infections, and genitourinary tract infections.

Associated Conditions: Bone Infection, Genitourinary tract infection, Otitis Media (OM), Respiratory Tract Infections (RTI), Skin and skin structure infections, Acute Prostatitis

Clinical Trials

Utility of Single-dose Oral Antibiotic Prophylaxis in Prevention of Surgical Site Infection in Dermatologic Surgery

Phase 4

Recruiting

Conditions: Surgical Site Infection

Interventions: Other: Placebo capsules
Drug: Cephalexin

First Posted Date: 2020-10-08

Last Posted Date: 2024-08-22

Lead Sponsor: Carilion Clinic

Target Recruit Count: 1600

Registration Number: NCT04580472

Locations: 🇺🇸
Carilion Clinic, Roanoke, Virginia, United States

Antibiotic Treatment Of Staphylococcus Aureus In Stable People With CF

Phase 3

Recruiting

Conditions: Cystic Fibrosis

Interventions: Drug: Placebo
Drug: Cephalexin

First Posted Date: 2020-09-17

Last Posted Date: 2022-01-14

Lead Sponsor: University of British Columbia

Target Recruit Count: 86

Registration Number: NCT04553419

Locations: 🇨🇦
BC Children's Hospital, Vancouver, British Columbia, Canada
🇨🇦
The Hospital For Sick Children, Toronto, Ontario, Canada

BonE and Joint Infections - Simplifying Treatment in Children Trial

Phase 4

Recruiting

Conditions: Bone Infection
Septic Arthritis
Bone and Joint Infection
Osteomyelitis

Interventions: Drug: Oral cefalexin only
Drug: IV cefazolin or IV flucloxacillin followed by oral cefalexin

First Posted Date: 2020-09-03

Last Posted Date: 2024-11-08

Lead Sponsor: Murdoch Childrens Research Institute

Target Recruit Count: 285

Registration Number: NCT04538053

Locations: 🇦🇺
Nepean Hospital, Kingswood, New South Wales, Australia
🇦🇺
John Hunter Children's Hospital, New Lambton Heights, New South Wales, Australia
🇦🇺
Sydney Children's Hospital Network, Sydney, New South Wales, Australia

and more 7 locations

High-dose vs. Standard-dose Cephalexin for Cellulitis

Phase 4

Completed

Conditions: Cellulitis

Interventions: Drug: Cephalexin
Drug: Cephalexin + placebo

First Posted Date: 2020-07-15

Last Posted Date: 2025-01-17

Lead Sponsor: Ottawa Hospital Research Institute

Target Recruit Count: 69

Registration Number: NCT04471246

Locations: 🇨🇦
The Ottawa Hospital, Ottawa, Ontario, Canada

Antibiotic Prophylaxis in High-Risk Arthroplasty Patients

Phase 4

Conditions: Inflammatory Disease
Tobacco Use
Infections Joint Prosthetic
Overweight or Obesity
Autoimmune Diseases
MSSA Colonization
MRSA
Chronic Kidney Diseases
Diabetes

Interventions: Drug: Cephalexin
Drug: Doxycycline
Drug: Cefadroxil

First Posted Date: 2020-03-05

Last Posted Date: 2024-06-27

Lead Sponsor: Mayo Clinic

Target Recruit Count: 4618

Registration Number: NCT04297592

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States

Cefadroxil and Cephalexin Drug Levels and Dosing in Pediatric Musculoskeletal Infections

Phase 1

Completed

Conditions: Septic Arthritis
Osteomyelitis
Pyomyositis

Interventions: Drug: Cefadroxil
Drug: Cephalexin

First Posted Date: 2019-01-14

Last Posted Date: 2021-06-02

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 17

Registration Number: NCT03802552

Locations: 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States

Antibiotics for Prevention of SSI in Obese Women Undergoing CS

Not Applicable

Conditions: Surgical Site Infection

Interventions: Drug: Cephalexin

First Posted Date: 2018-11-09

Last Posted Date: 2018-11-09

Lead Sponsor: Ain Shams University

Target Recruit Count: 280

Registration Number: NCT03736187

The Effect of Prophylactic Antibiotics on Surgical Site Infection Lower Limb Skin Excisions

Not Applicable

Withdrawn

Conditions: Skin Lesion

Interventions: Drug: Cephalexin
Drug: Placebo oral capsule

First Posted Date: 2017-11-29

Last Posted Date: 2022-05-04

Lead Sponsor: Rambam Health Care Campus

Registration Number: NCT03357419

Locations: 🇮🇱
Department of Plastic Surgery, Rambam Medical Center, Haifa, Israel

Prophylactic Antibiotics After Cesarean

Phase 1

Completed

Conditions: Surgical Site Infection

Interventions: Drug: Cephalexin
Drug: Placebo
Drug: Metronidazole

First Posted Date: 2017-06-14

Last Posted Date: 2023-08-16

Lead Sponsor: The University of Texas Medical Branch, Galveston

Target Recruit Count: 321

Registration Number: NCT03187106

Locations: 🇺🇸
St. David's North Austin Medical Center, Austin, Texas, United States
🇺🇸
University of Texas Medical Branch John Sealy Hospital, Galveston, Texas, United States

Impact of Antibiotic Treatment Following Implantation of Cardiac Electronic Device on Patient's Outcome

Phase 4

Conditions: Pacemaker Complication
Infection, Bacterial

Interventions: Drug: cefalexin 500 mg qid or roxithromycin 150 mg bid

First Posted Date: 2017-05-11

Last Posted Date: 2017-05-11

Lead Sponsor: Kaplan Medical Center

Target Recruit Count: 400

Registration Number: NCT03148444

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy